UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

When prospective randomised trials have unexpected results: where do we go from there?

BJOG : an international journal of obstetrics and gynaecology, 2019-07, Vol.126 (8), p.960-960

Duska, LR

2019

Volltextzugriff (PDF)

Granulosa cell tumours of the ovary: the challenges of studying a rare tumour

BJOG : an international journal of obstetrics and gynaecology, 2017-01, Vol.124 (1), p.149-149

Duska, LR

2017

Volltextzugriff (PDF)

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Gynecologic oncology, 2021-03, Vol.160 (3), p.688-695

2021

Volltextzugriff (PDF)

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Annals of oncology, 2018-10, Vol.29, p.viii404-viii405

2018

Volltextzugriff (PDF)

Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors

European journal of cancer (1990), 2022-10, Vol.174, p.S67-S67

2022

Volltextzugriff (PDF)

Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies

European journal of cancer (1990), 2022-10, Vol.174, p.S31-S32

2022

Volltextzugriff (PDF)

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Cytokines IL‐1β, IL‐2, IL‐6, IL‐8, MCP‐1, GM‐CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

International journal of gynecological cancer, 2000-01, Vol.10 (1), p.33-41

2000

Volltextzugriff (PDF)

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

Annals of oncology, 2017-11, Vol.28 Suppl 8, p.viii8

2017

Volltextzugriff (PDF)

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

International journal of gynecological cancer, 2006-01, Vol.16 (Suppl 1), p.267-272

2006

Volltextzugriff (PDF)

LBA60Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)

Annals of oncology, 2016-10, Vol.27, p.vi298-vi298

2016

Volltextzugriff (PDF)

Hypersensitivity reactions to cetuximab

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13054-e13054

2011

Volltextzugriff (PDF)

A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5021-5021

2010

Volltextzugriff (PDF)

Advanced stage serous papillary ovarian cancer: Impact of histological grade in clinical outcomes

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16579-16579

2008

Volltextzugriff (PDF)

Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5017-5017

2011

Volltextzugriff (PDF)

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5066-5066

2011

Volltextzugriff (PDF)

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5047-5047

2011

Volltextzugriff (PDF)

Comparison of the quality of life of early and advanced stage ovarian cancer survivors

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5528-5528

2008

Volltextzugriff (PDF)

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5523-5523

2008

Volltextzugriff (PDF)

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

International journal of gynecological cancer, 2000-01, Vol.10 (1), p.33-41

2000

Volltextzugriff (PDF)

Biodistribution of charged F(ab') photoimmunoconjugates in a xenograft model of ovarian cancer

British journal of cancer, 1997-03, Vol.75 (6), p.837-844

1997

Volltextzugriff (PDF)

Predictors of recurrence in surgical stage II endometrial adenocarcinoma1

Gynecologic oncology, 1999, Vol.73 (3), p.407-411

1999

Volltextzugriff (PDF)

Clinical Evaluation of Atypical Glandular Cells of Undctermined Significance on Cervical Cytology

Journal of lower genital tract disease, 1998-07, Vol.2 (3), p.163

1998

Volltextzugriff (PDF)

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

Gynecologic oncology, 2024-05, Vol.184, p.8-15

2024

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(83)
Buchkapitel
(6)

Sprache

Englisch
(89)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

When prospective randomised trials have unexpected results: where do we go from there?

Granulosa cell tumours of the ovary: the challenges of studying a rare tumour

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors

Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Cytokines IL‐1β, IL‐2, IL‐6, IL‐8, MCP‐1, GM‐CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

LBA60Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC)

Hypersensitivity reactions to cetuximab

A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer

Advanced stage serous papillary ovarian cancer: Impact of histological grade in clinical outcomes

Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD)

Comparison of the quality of life of early and advanced stage ovarian cancer survivors

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

Biodistribution of charged F(ab') photoimmunoconjugates in a xenograft model of ovarian cancer

Predictors of recurrence in surgical stage II endometrial adenocarcinoma1

Clinical Evaluation of Atypical Glandular Cells of Undctermined Significance on Cervical Cytology

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

Aktive Filter

Suchergebnisse filtern